Background Drug-resistant tuberculosis (DR-TB) is undermining TB control in South Africa. However, there are hardly any data about the cost of treating DR-TB in high burden settings despite such information being quintessential for the rational planning and allocation of resources by policy-makers, and to inform future cost-effectiveness analyses. Methodology We analysed the comparative 2011 United States dollar ($) cost of diagnosis and treatment of drug sensitive TB (DS-TB), MDR-TB and XDR-TB, based on National South African TB guidelines, from the perspective of the National TB Program using published clinical outcome data. Principal Findings Assuming adherence to national DR-TB management guidelines, the per patient cost of XDR-TB was $26,392, four times greater than MDR-TB ($6772), and 103 times greater than drug-sensitive TB ($257). Despite DR-TB comprising only 2.2% of the case burden, it consumed ~32% of the total estimated 2011 national TB budget of US $218 million. 45% and 25% of the DR-TB costs were attributed to anti-TB drugs and hospitalization, respectively. XDR-TB consumed 28% of the total DR-TB diagnosis and treatment costs. Laboratory testing and anti-TB drugs comprised the majority (71%) of MDR-TB costs while hospitalization and anti-TB drug costs comprised the majority (92%) of XDR-TB costs. A decentralized XDR-TB treatment programme could potentially reduce costs by $6930 (26%) per case and reduce the total amount spent on DR-TB by ~7%. Conclusion/Significance Although DR-TB forms a very small proportion of the total case burden it consumes a disproportionate and substantial amount of South Africa’s total annual TB budget. These data inform rational resource allocation and selection of management strategies for DR-TB in high burden settings.
References
[1]
World Health Organization (2011) WHO Report 2011: Global Tuberculosis Control. (2011) Available: http://www.who.int/tb/publications/globa？l_report/en/. Accessed 2012 Oct 20.
[2]
United Nations (2011) The UN Millenium Development Goals Report 2011 (2011) Available: www.un.org/millenniumgoals/reports.shtml.Accessed 2012 Mar.
[3]
Dheda K, Migliori GB (2012) The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 379: 773–775.
[4]
Dheda K, Warren RM, Zumla A, Grobusch MP (2010) Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 24: 705–725.
[5]
South African Department of Health (2011) Management of Drug-Resistant Tuberculosis: Policy Guidelines (2011) Available: www.kznhealth.gov.za/pharmacy/ptc/MDR201？1.pdf.Accessed 2012 Oct 3.
[6]
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al. (2010) Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. The Lancet 375: 1798–1807.
[7]
Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, et al. (2011) Extensively Drug-Resistant TB in Eastern Cape, South Africa: High Mortality in HIV-Negative and HIV-Positive Patients. J Acquir Immune Defic Syndr 57: 146–152.
[8]
O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR (2009) Improved early results for patients with extensively drug resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 13: 855–861.
[9]
Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB (2010) Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51: 6–14.
[10]
World Health Organization (2011) Tuberculosis Country Profiles: South Africa (2011) Available: http://www.who.int/tb/country/data/profi？les/en/index.html.Accessed 2012 Jul.
[11]
Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7: e36966.
[12]
Oxlade O, Falzon D, Menzies D (2012) The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis. Eur Respir J 39: 626–634.
[13]
Resch SC, Salomon JA, Murray M, Weinstein MC (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3: e241.
[14]
Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359: 1980–1989.
[15]
Tupasi TE, Gupta R, Quelapio MID, Orillaza RB, Mira NR, et al. (2006) Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 3: e352.
[16]
White VLC, Moore-Gillon J (2000) Resource implications of patients with multidrug resistant tuberculosis. Thorax 55: 962.
[17]
Fitzpatrick C, Floyd K (2012) A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. Pharmacoeconomics 30: 63–80.
[18]
Statistics South Africa (2012) Statistical Release P0141 - Consumer Price Index August 2012 (2012) Available: http://www.statssa.gov.za/publications/P？0141/P0141August2012.pdf.Accessed 2012 Oct 22.
[19]
United Nations (2011) Operational Rates of Exchange. (2011) Available: http://treasury.un.org. Accessed 2011 Dec.
[20]
Brust JCM, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2011) Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PloS one 6: e15841.
[21]
Calver AD, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. (2010) Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 16: 264–271.
[22]
Farley JE, Ram M, Pan W, Waldman S, Cassell GH, et al. (2011) Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PloS one 6: e20436.
[23]
Heller T, Lessells RJ, Wallrauch CG, Barnighausen T, Cooke GS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420–426.
[24]
Iddriss A, Reddy D, Padayatchi N, Reddi A (2011) Pulmonary resection for extensively drug-resistant tuberculosis in Durban, South Africa. Joint Meeting of 19th ASCVTS and 21st ATCSA. Phuket, Thailand.
[25]
Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, et al. (2008) Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 65: 396–406.
[26]
Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382–1384.
[27]
Schaaf HS, Moll AP, Dheda K (2009) Multidrug-and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin Chest Med 30: 667–683, vii–viii.
[28]
Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, et al. (2009) Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PloS one 4: e7186.
[29]
Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, et al. (2008) Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 19922002. Int J Tuberc Lung Dis 12: 1182–1189.
[30]
Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, et al. (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33: 871–881.
[31]
World Health Organization (2002) Guidelines for cost and cost-effectiveness analysis of tuberculosis control. (2002) Available: http://whqlibdoc.who.int/hq/2002/WHO_CDS？_TB_2002.305b.pdf. Accessed 2012 Jun 18.
[32]
Cleary SM, McIntyre D, Boulle AM (2006) The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa–a primary data analysis. Cost Eff Resour Alloc 4: 20.
[33]
World Health Organization (2011) Rapid Implementation of the Xpert MTB/RIF diagnostic test (2011) Available: http://whqlibdoc.who.int/publications/20？11/9789241501569_eng.pdf.Accessed 2012 Oct 22.
[34]
South African Department of Health (2009) National Tuberculosis Management Guidelines (2009) Available: http://familymedicine.ukzn.ac.za/Librari？es/Guidelines_Protocols/TB_Guidelines_20？09.sflb.ashx.Accessed 2012 Aug 12.
[35]
World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. (2006) Available: http://www.who.int/tb/challenges/mdr/pro？grammatic_guidelines_for_mdrtb/en/index.？html. Accessed 2012 Oct 21.
[36]
Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER (2000) Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34: 1373–1379.
[37]
Arbex MA, Varella Mde C, Siqueira HR, Mello FA (2010) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol 36: 641–656.
[38]
Schwartzman K, Menzies D (2000) Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 161: 780–789.
[39]
Pooran A, Booth H, Miller RF, Scott G, Badri M, et al. (2010) Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 10: 7.
[40]
Global Issues Health: High Drug Prices Hamper Drug-Resistant TB Treatment (2011) Available: http://www.globalissues.org/news/2011/06？/17/10134.Accessed 2011 Apr.
[41]
Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert (R) MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132–140.
[42]
Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, et al. (2007) Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. The Lancet 370: 1500–1507.
[43]
World Health Organization (2005) Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti- Tuberculosis Drug Resistance Surveillance. Report no. 3. Prev-alence and trends. WHO/HTM/TB/2004.343. Geneva, Switzer-land (2005).
[44]
South African Department of Health. Tuberculosis Strategic Plan for South Africa, 2007–2011. Available: http://www.info.gov.za/view/DownloadFile？Action?id=72544. Accessed 2012 Apr 10.
